Mineralys Therapeutics, Inc. (MLYS)
NasdaqGS · USD · Healthcare · Biotechnology
$20.56 (+0.05%) as of
Key statistics
- Market cap
- 1.82B
- Forward P/E
- -8.37
- EPS (TTM)
- -4.22
- Dividend yield
- 0.00%
- 52-week range
- 20.12 – 47.65
- Beta
- 0.69
- Profit margin
- 0.00%
- Analyst target
- $46.33
- Volume
- 767.16k
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Radnor, PA, United States
- Employees
- 76
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.